You are here: Industry Insights > NMPA

News List

Yichang Humanwell’s Class 3 Generic Drug Alfentanil Hydrochloride Approved for Marketing PharmaSources/Caicai
March 16, 2020
The drug becomes one of the first alfentanil drugs approved for marketing in China. Alfentanil Hydrochloride Injection is a potent analgesic used for anesthesia and applies to short surgical procedures.
Jiangsu Hengrui's Second Indication Application for Camrelizumab to be Approved for Marketing in China En-CPhI.CN
February 28, 2020
According to NMPA, the second indication of Jiangsu Hengrui's PD-1Camrelizumab to treat liver cancer is close to be approved for martketing soon.
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA prnasia
February 18, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today the application for in-house developed Category 1 Drug ASC41 for clinical trials of NASH indication has been accepted by China's National Medical Products Administration (NMPA).
Numbers of Drug Approval by FDA, EMA and NMPA in 2019 En-CPhI.Cn
January 23, 2020
A quick review of drug approval in the past 2019 by NMPA, EMA and FDA.
Sinovac Announces Approval of Varicella Vaccine for Chickenpox in China americanpharmaceuticalreview
January 07, 2020
Sinovac Biotech announced the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company’s varicella vaccine to prevent the varicella-zoster virus in children from 1 to 12 years old.
Zai Lab Announces NMPA Approval of ZEJULA in China americanpharmaceuticalreview
January 02, 2020
Zai Lab announced the China National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for ZEJULA (niraparib) ...
Timetable reportedly set for national vaccine tracking system in China europeanpharmaceuticalreview
December 18, 2019
A national vaccine tracking system in China will aim to be completed before 31 March 2020, a report has said.
Shanghai Green Valley’s Class 1 New Drug for Alzheimer’s Disease Conditionally Approved for Marketing and Already Having the Registration Approval! PharmaSources/Caicai
November 14, 2019
The National Medical Products Administration of China (NMPA) released on its website yesterday (Nov. 2, 2019) some big news that shocks the industry.
China NMPA Approves Bio-Thera Solutions’ QLETLI®, A Biosimilar To Humira® (Adalimumab) bio-thera
November 08, 2019
Approval Based on Totality of Evidence Demonstrating That QLETLI® Is Biosimilar to Humira® First Approved Biosimilar From Bio-Thera's Biosimilar Portfolio.
NMPA approves oral formulation of Akynzeo in China biospectrumasia
September 25, 2019
Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: "Lack of control of CINV is a problem despite the availability of several antiemetics. We are pleased that Akynzeo® that targets two CINV critical pathways in a single dose will help patient

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page